Replies to post #49709 on $heff's $tation of $tocks & $olid DD

[ronpopeil]

I know many stocks that have gone down after the FDA approves their drug. Most people are surprised. However, the truth is many of these newly FDA approved drugs will be commercial busts and/or these companies do not have the capital to really bring them to market. They will rely on heavily diluting their share structure to move the drug to the market. AIS is different. Anturol will not be a commercial bust. Based on the results it will be a market leader in the overactive bladder market which is over $3 billion based on its efficacy and safety profile. In addition, they have a heavyweight, Watson Pharmaceuticals, that will use it enormous financial resources and muscle to bring it to market. AIS is in a win/win situation. I don't expect a sell off after approval unless the AIS runs up a lot beforehand and even then, i expect it to pop back up soonafter. In addition, AIS has many other irons in the fire such as Libigel and Vibex to name a few.